Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Add filters

Document Type
Year range
Arch Virol ; 166(3): 675-696, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1064514


The number of descriptions of emerging viruses has grown at an unprecedented rate since the beginning of the 21st century. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is the third highly pathogenic coronavirus that has introduced itself into the human population in the current era, after SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Molecular and cellular studies of the pathogenesis of this novel coronavirus are still in the early stages of research; however, based on similarities of SARS-CoV-2 to other coronaviruses, it can be hypothesized that the NF-κB, cytokine regulation, ERK, and TNF-α signaling pathways are the likely causes of inflammation at the onset of COVID-19. Several drugs have been prescribed and used to alleviate the adverse effects of these inflammatory cellular signaling pathways, and these might be beneficial for developing novel therapeutic modalities against COVID-19. In this review, we briefly summarize alterations of cellular signaling pathways that are associated with coronavirus infection, particularly SARS-CoV and MERS-CoV, and tabulate the therapeutic agents that are currently approved for treating other human diseases.

COVID-19/pathology , Middle East Respiratory Syndrome Coronavirus/metabolism , SARS-CoV-2/metabolism , Signal Transduction/physiology , COVID-19/drug therapy , Cytokines/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Inflammation/pathology , Middle East Respiratory Syndrome Coronavirus/drug effects , NF-kappa B/metabolism , SARS-CoV-2/drug effects , Tumor Necrosis Factor-alpha/metabolism